The foundation of our transdermal business was established through strong partnerships.
Corium has demonstrated a strong track record of developing complex transdermal products for partners and manufacturing them for clinical development and commercial sale. Today, we have built on this foundation to create a balanced business model, allowing us to build a high-value proprietary CNS pipeline while continuing to create value for existing and new partners.
Corium’s two lead proprietary product candidates are focused on the treatment of Alzheimer’s disease:
|Corplex Donepezil||Alzheimer’s Disease||Pilot BE|
|Corplex Memantine||Alzheimer’s Disease||Phase 1|
|Corplex Ropinirole||Parkinson’s Disease||Preclinical|
|MicroCor hPTH(1-34)||Osteoporosis||Phase 2|
|MicroCor Zolmitriptan||Acute Migraine||Preclinical|
Our partnered programs include commercial and development-stage transdermal product opportunities:
|Crest® Whitestrips (5 Products)||Teeth Whitening||Marketed|
|Undisclosed||Motion Sickness||ANDA Filed|